Effect Of Dagliazine On Cardiac Function In Patients With Mild Ejection Fraction Decrease In Heart Failure

Objective(s): To explore the clinical effect of dagliazine on patients with mild ejection fraction decrease in heart failure,improve the understanding of patients with mild ejection fraction decrease in heart failure,more standardized diagnosis and treatment of patients.Methods: Patients diagnosed as having mildly decreased ejection fraction heart failure in outpatients and hospitalized patients of the First People’s Hospital of Yunnan Province from November 1,2021 to December 31,2022 were chosen and stochastically assigned to conventional anti-heart failure set and dagliazine set according to whether or not they took dagliazine.Baseline data of patients in the two sets were collected,including age,gender,blood pressure,co-existing diseases,drug use,etc.,and cardiac function changes,inter-group and intra-group echocardiogram results of patients in the two sets were studied after three months,six months,and one year after cure: LVEDD(left ventricular end-diastolic diameter),LVESD(left ventricular end-systolic diameter),LVEF(left ventricular ejection fraction),IVST(ventricular septal thickness),LVPWT(left ventricular posterior wall thickness),LAD(left atrial diameter)and the occurance of bad effect within one year were statistically analyzed,and P<0.05 was statistically significant.Results: In this study,70 patients were enrolled for statistical analysis according to inclusion criteria and exclusion criteria,33 patients taking dagliazine orally,including19 patients with diabetes.There were 37 patients simply using ordinary anti-heart failure,including 16 patients with diabetes.They have no statistically markedly diversity in the dagliazine set and the conventional anti-heart failure set on baseline data.After three months,six months and one year of arrangement,the cardiac function in both sets was enhanced comparing with that before cure.The overall response rate of dagliazine set signally exceeded in that of conventional anti-heart failure set(P<0.05).Intra-group comparison of cardiac ultrasound indexes after cure:LVEF in two sets was overtop that before cure,LVEDD,LVESD,LAD,IVST and LVPWT were inferior to that before treatment,P<0.05.After cure,there were no prominent discrepancise in LVEF,LVEDD,LVESD,LAD and IVST in the two sets after three months,P>0.05.The reduction of LVPWT in dagliazine set was memorably exceeded in that in conventional anti-heart failure set(P<0.05).Six months and one year after cure,LVEF in dagliazine set was markedly rised,and LAD,IVST and LVPWT were markedly reduced than those in conventional anti-heart failure set,P<0.05;There was no markedly discrepancy in the reduction of LVEDD and LVESD six months after cure(P>0.05),but the discrepancy was statistically prominent after one year cure(P<0.05).After one year of arrangement,no patients in dagliazine set showed hypoglycemia,hypotension or renal function damage.In the conventional anti-heart failure set,three cases of hypoglycemia,three cases of hypotension and five cases of renal function damage,with no statistical discrepancy(P>0.05).Urinary tract infection happened in one patient in dagliazine set,while none of patients in conventional anti-heart failure set,with no statistical discrepancy(P=0.471).Conclusion(s): 1.On the basis of standardized anti-heart failure drug therapy,combined with dagliazine can further increase cardiac function in patients with HFmr EF.2.Dagliazine is safe and reliable in the cure of HFmr EF patients,with a low occurrence of untoward effect.